Rhythm PharmaceuticalsRYTM
About: Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
Employees: 283
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
521% more call options, than puts
Call options by funds: $21.5M | Put options by funds: $3.46M
130% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 20
23% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 69
12% more funds holding
Funds holding: 202 [Q4 2024] → 227 (+25) [Q1 2025]
3.33% less ownership
Funds ownership: 105.6% [Q4 2024] → 102.27% (-3.33%) [Q1 2025]
6% less capital invested
Capital invested by funds: $3.63B [Q4 2024] → $3.43B (-$207M) [Q1 2025]
36% less funds holding in top 10
Funds holding in top 10: 11 [Q4 2024] → 7 (-4) [Q1 2025]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
Needham Joseph Stringer | 15%upside $72 | Buy Maintained | 7 May 2025 |
B of A Securities Tazeen Ahmad | 9%upside $68 | Buy Maintained | 10 Apr 2025 |
HC Wainwright & Co. Raghuram Selvaraju | 28%upside $80 | Buy Reiterated | 8 Apr 2025 |
Canaccord Genuity Whitney Ijem | 47%upside $92 | Buy Maintained | 8 Apr 2025 |
Wells Fargo Derek Archila | 46%upside $91 | Overweight Maintained | 7 Apr 2025 |
Financial journalist opinion
Based on 8 articles about RYTM published over the past 30 days









